These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2779475)

  • 1. Tetrahydroaminoacridine (THA) as a pharmacological probe in Alzheimer's disease (AD) and other neurodegenerative disorders.
    Sattin A; Muhoberac BB; Aprison MH; Schauf CL
    Med Hypotheses; 1989 Jul; 29(3):155-9. PubMed ID: 2779475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease and THA: a review of the cholinergic theory and of preliminary results.
    Boller F; Forette F
    Biomed Pharmacother; 1989; 43(7):487-91. PubMed ID: 2684292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological significance of acetylcholinesterase inhibition by tetrahydroaminoacridine.
    Marquis JK
    Biochem Pharmacol; 1990 Sep; 40(5):1071-6. PubMed ID: 2390104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple actions of THA on cholinergic neurotransmission in Alzheimer brains.
    Nordberg A; Nilsson-Håkansson L; Adem A; Lai Z; Winblad B
    Prog Clin Biol Res; 1989; 317():1169-78. PubMed ID: 2557636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent Alzheimer's disease.
    Kumar V; Becker RE
    Int J Clin Pharmacol Ther Toxicol; 1989 Oct; 27(10):478-85. PubMed ID: 2684868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 9-amino-1,2,3,4-tetrahydroacridine (THA), a potential drug for treatment of Alzheimer's disease, on the physical state of human erythrocyte membranes.
    Palmieri DA; Butterfield DA
    Prog Clin Biol Res; 1989; 292():419-24. PubMed ID: 2726917
    [No Abstract]   [Full Text] [Related]  

  • 7. Spin-labelling studies of the interaction of 9-amino-1,2,3,4-tetrahydroacridine (THA), a proposed drug for the treatment of Alzheimer's disease, with erythrocyte membranes.
    Butterfield DA; Palmieri DA
    Free Radic Res Commun; 1990; 9(3-6):361-6. PubMed ID: 2167274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mechanism of tetrahydroaminoacridine-evoked release of endogenous 5-hydroxytryptamine and dopamine from rat brain tissue prisms.
    Robinson TN; De Souza RJ; Cross AJ; Green AR
    Br J Pharmacol; 1989 Dec; 98(4):1127-36. PubMed ID: 2611486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro.
    Hunter AJ; Murray TK; Jones JA; Cross AJ; Green AR
    Br J Pharmacol; 1989 Sep; 98(1):79-86. PubMed ID: 2804555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetrahydroaminoacridine inhibits human and rat brain monoamine oxidase.
    Adem A; Jossan SS; Oreland L
    Neurosci Lett; 1989 Dec; 107(1-3):313-7. PubMed ID: 2616041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 9-Amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ current.
    Drukarch B; Kits KS; Van der Meer EG; Lodder JC; Stoof JC
    Eur J Pharmacol; 1987 Sep; 141(1):153-7. PubMed ID: 2444444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles.
    Mesulam MM; Geula C; Morán MA
    Ann Neurol; 1987 Dec; 22(6):683-91. PubMed ID: 3435078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. THA increases action potential duration of central histamine neurons in vitro.
    Reiner PB; McGeer EG
    Eur J Pharmacol; 1988 Oct; 155(3):265-70. PubMed ID: 3148476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine.
    Flynn DD; Mash DC
    J Pharmacol Exp Ther; 1989 Aug; 250(2):573-81. PubMed ID: 2760841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrahydroaminoacridine (THA) in Alzheimer's disease.
    Byrne J; Arie T
    BMJ; 1989 Apr; 298(6677):845-6. PubMed ID: 2497817
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of tetrahydroaminoacridine on M1 and M2 muscarine receptors.
    Pearce BD; Potter LT
    Neurosci Lett; 1988 Jun; 88(3):281-5. PubMed ID: 3386874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
    Chatellier G; Lacomblez L
    BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physostigmine and tetrahydroaminoacridine treatment of Alzheimer's disease.
    Gustafson L
    Acta Neurol Scand Suppl; 1993; 149(Rand):39-41. PubMed ID: 8128836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrine in the treatment of Alzheimer's disease. A clinical update and recent pharmacologic studies.
    Summers WK; Tachiki KH; Kling A
    Eur Neurol; 1989; 29 Suppl 3():28-32. PubMed ID: 2693104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose tetrahydroaminoacridine (THA) improves cognitive function but does not affect brain acetylcholine in rats.
    Hodges H; Ribeiro AM; Gray JA; Marchbanks RM
    Pharmacol Biochem Behav; 1990 Jun; 36(2):291-8. PubMed ID: 2356203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.